ACTUATE THERAPEUTICS, INC. — Form S-1
Filed October 6, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 28/100
What the filing says
Actuate Therapeutics, Inc. entered into an underwriting agreement with Konik Capital Partners LLC (representative) for an IPO of common stock. Key terms: Firm shares at 93% of public offering price; 15% over-allotment option (Option Shares); Konik receives warrants equal to 3.5% of total public securities at 125% of offering price, exercisable 180 days post-effective date through 5-year expiration; lock-up period of 120 days for officers/directors (or 2 years for major investors). Specific dollar amounts and share counts are redacted (marked with placeholder symbols).
Why this rating
Standard IPO underwriting agreement with typical SPAC-era warrant and lock-up terms. Redacted financials prevent full assessment. Warrant dilution (3.5%) and underwriter compensation are ordinary. No M&A, no stated revenue or clinical data impact. Routine capital-raising event for micro-cap biotech.
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.